For over five decades, Seraplex has supplied global diagnostic and therapeutic manufacturers with high-quality biological specimens. The company has evolved from standard offerings to specialized, disease-state products, a shift that positions it well within the rapidly expanding fields of precision medicine and biomarker discovery.

Rose Maljanian, Managing Director at WaveEdge, noted that the integration of Seraplex with Prairie Capital’s existing portfolio creates a significant suite of resources for the biopharmaceutical sector. Chicago-based Prairie Capital specializes in scaling founder-owned businesses, intending to leverage its multi-sector expertise to accelerate the growth of its new acquisition. The WaveEdge deal team, led by Maljanian and John Selig, managed the transaction as part of their ongoing focus on the life sciences and healthcare lower middle market.